Business News • PR NewsWire • Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

THOUSAND OAKS, Calif., March 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha™...

View More : http://www.prnewswire.com/news-releases/amgen-publishes-safety-analysis-of-investigational-cholesterol-lowering-medicati...

Releted News by prnewswire

Stephen Curry & Degree Men® Set to Kick Off 48 Hours of Game-Changing NCAA® March Madness®

World-first Live Streaming Virtual Reality Birth Using Samsung Gear VR

XCOR Aerospace Announces Jay Gibson As New Chief Executive Officer

Flyer Preferences: Savings Matter More Than Movies, Meals In APAC